Skip to content
Back to ACRS

Aclaris Therapeutics, Inc.

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 18, 2025
Transactions
1
Purchases
0
Sales
1
Purchase value
$0.00
Sale value
$1.36M

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Leonard Braden Michael10% owner
4
Filed Apr 27, 2026Period of report Apr 27, 20260001373604-26-000034
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleApr 23, 2026
Common StockF1300,000$4.53$1.36M13,950,000IndirectHoldings of BML Investment Partners, L.P.
Filing footnotes · 1
  1. F1BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.